Veeva Systems (VEEV) · Software
Veeva Systems Q2 FY2027 earnings: summary, key numbers & outlook
Results filed 26 Aug 2026 · Quarter ended 31 Jul 2026
Slides (17 pages)Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Veeva's Vault CRM had its best quarter ever, with 12 top 20 biopharma commitments, while Veeva Falcon agentic AI for clinical, regulatory and safety moves toward first go-lives.
Veeva's push into AI-driven applications gained traction. Vault CRM has more than 180 customers live, including five top 20 biopharmas, and a top 20 biopharma rolled out Vault CRM with the Agentic Call Report to its full U.S. field team. Development Cloud and Quality Cloud saw broad adoption: a large biopharma selected Veeva EDC, Veeva Safety passed 100 customers, and Quality added more than 30 new customers. Veeva also acquired Copli and launched Veeva Falcon MLR.
Management is steering toward agentic labor: Veeva Falcon has five early adopters and is on track for initial go-lives this year, alongside new standard agents in Vault AI. The main tension is execution. Falcon is a new product that must be readied and proven with early adopters, while Veeva's services business is growing faster than subscriptions as customers adopt new products. Headcount is up 11% year over year.
No call transcript for this quarter, so this summary also draws on: Benzinga (republished on Webull) ↗.
Slides & documents
Open the slide deck (PDF, 17 pages) ↗
Showing the first 6 of 17 pages.
From Veeva Systems investor relations
- Prepared RemarksCFO commentary ↗
- WebcastWebcast replay ↗
- Financial ResultsDocument ↗
- Financial Results (HTML)Document ↗
SEC filing
Key numbers
- Total revenues · GAAP
- $928.0 million
- Net income · GAAP
- $273.4 million
- Diluted EPS · GAAP
- $1.66
- Non-GAAP diluted EPS · non-GAAP
- $2.35
- Operating income · GAAP
- $275.0 million
- Non-GAAP operating income · non-GAAP
- $415.9 million
- Gross margin · GAAP
- 75.0%
- Operating margin · GAAP
- 29.6%
up 18% year over year
up 37% year over year
up from $1.19 one year ago
up from $1.99 one year ago
up 40% year over year
up 18% year over year
from 75.3% a year ago
from 24.8% a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Subscription revenues | $766.8 million | up 16% year over year |
| Commercial Solutions subscription | $347.4M | from $307,523 a year ago |
| R&D and Quality Solutions subscription | $419.4M | from $351,660 a year ago |
| Professional services and other | $161.2M | from $129,898 a year ago |
| Vault CRM customers live | more than 180 | |
| Veeva Safety customers | 100 total customers |
Where each number comes from
- Total revenues: “Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year.”
- Net income: “Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year.”
- Diluted EPS: “For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.”
- Non-GAAP diluted EPS: “For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.”
- Operating income: “Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year.”
- Non-GAAP operating income: “Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year.”
- Gross margin: “Gross margin on total revenues on a GAAP basis | 75.0% | 75.3% | 75.0% | 76.2%”
- Operating margin: “Operating margin on a GAAP basis | 29.6% | 24.8% | 30.3% | 27.8%”
- Subscription revenues: “Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year.”
- Commercial Solutions subscription: “Veeva Commercial Solutions | $347,389 | $307,523 | $685,255 | $612,934”
- R&D and Quality Solutions subscription: “Veeva R&D and Quality Solutions | 419,375 | 351,660 | 811,684 | 681,017”
- Professional services and other: “Total professional services and other | $161,199 | $129,898 | $313,972 | $254,173”
- Vault CRM customers live: “Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas.”
- Veeva Safety customers: “Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 FY2027 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $928.0M | +17.6% | +5.1% |
| Operating income | $275.0M | +40.4% | +0.7% |
| Net income | $273.4M | +36.5% | +4.8% |
| Diluted EPS | $1.66 | +39.5% | +5.7% |
| Gross margin | 75.0% | −0.3 pts | +0.0 pts |
| Operating margin | 29.6% | +4.8 pts | −1.3 pts |
Calculated by code from XBRL, not by the model.
Guidance check
| Metric | Outlook given with Q1 FY2027 | Reported | Result |
|---|---|---|---|
| Revenue | $902 and $905 million | $928.0M | above the range |
| EPS (non-GAAP) | $2.21 and $2.22 | $2.35 | above the range |
Compared with the company's own guidance, not analyst estimates, and only where the outlook and the reported figure are the same measure on the same basis. Ranges are worked out by code from the company's wording. How this works.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Total revenues | fiscal third quarter ending October 31, 2026 | $932 and $935 million |
| Non-GAAP operating income | fiscal third quarter ending October 31, 2026 | $417 and $420 million |
| Non-GAAP diluted EPS | fiscal third quarter ending October 31, 2026 | $2.33 and $2.34 |
| Total revenues | fiscal year ending January 31, 2027 | $3,682 and $3,687 million |
| Non-GAAP operating income | fiscal year ending January 31, 2027 | ~$1,640 million |
| Non-GAAP diluted EPS | fiscal year ending January 31, 2027 | ~$9.21 |
| Non-GAAP operating cash flow | fiscal year ending January 31, 2027 | ~$1,600 million |
Key takeaways
Vault CRM momentum builds among largest biopharmas
More than 180 customers are live, including five top 20 biopharmas, and two top 20 plus one large enterprise biopharma committed in August, bringing top 20 commitments to 12. This strengthens Veeva's position in its core commercial market.
Agentic CRM is reaching full field deployment
A top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. It is a concrete example of AI moving into production use.
Veeva Falcon targets clinical, regulatory and safety labor
Falcon is described as an agentic labor platform with five early adopters and initial go-lives expected this year. Veeva also launched Veeva Falcon MLR to automate content reviews.
Vault AI broadens with standard and custom agents
August brought new standard agents, broader capabilities for existing agents, and advanced tools for building custom agents. This extends AI from Veeva's own agents to customer-built ones.
R&D and Quality footprint keeps widening
A large enterprise biopharma selected Veeva EDC on top of eTMF, CTMS and Study Startup, and Veeva Safety won its second top 20 biopharma for Safety Workbench. Quality added more than 30 new customers, with 20 or more wins each across QualityDocs, QMS and Training.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $699.2M |
| Q4 FY25 | $720.9M * |
| Q1 FY26 | $759.0M |
| Q2 FY26 | $789.1M |
| Q3 FY26 | $811.2M |
| Q4 FY26 | $836.0M * |
| Q1 FY27 | $882.9M |
| Q2 FY27 | $928.0M |
Data
| Q3 FY25 | $1.13 |
| Q1 FY26 | $1.37 |
| Q2 FY26 | $1.19 |
| Q3 FY26 | $1.40 |
| Q1 FY27 | $1.57 |
| Q2 FY27 | $1.66 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 25.9% |
| Q4 FY25 | 26.1% |
| Q1 FY26 | 30.8% |
| Q2 FY26 | 24.8% |
| Q3 FY26 | 29.7% |
| Q4 FY26 | 29.4% |
| Q1 FY27 | 30.9% |
| Q2 FY27 | 29.6% |
Questions
What were the main product developments at Veeva this quarter?
Veeva launched Veeva Falcon MLR, advanced Vault AI with new standard agents and custom agent tools, and acquired Copli. Veeva Falcon, its agentic platform for clinical, regulatory and safety, has five early adopters.
How is Vault CRM doing with large pharma customers?
More than 180 customers are live, including five top 20 biopharmas. Top 20 commitments reached 12 globally after two top 20 biopharmas and one large enterprise biopharma committed in August.
When will Veeva Falcon go live?
Veeva says Falcon is on track for initial go-lives this year, with five early adopters working with it now.
Is Veeva gaining ground in clinical, safety and quality software?
Yes, according to the release. A large biopharma selected Veeva EDC, Veeva Safety passed 100 customers with a second top 20 Safety Workbench win, and Quality added more than 30 new customers.
How is Veeva positioning itself around AI?
Veeva describes AI as the next big chapter and combines applications, agents, data and consulting for life sciences. Its AI offerings include Vault AI agents, the Agentic Call Report and Falcon agentic labor.





